Journal of International Obstetrics and Gynecology ›› 2020, Vol. 47 ›› Issue (1): 88-91.

Previous Articles     Next Articles

Research Progress on Irisin and Metabolic Disorders of Polycystic Ovary Syndrome

LI Yang,YAN Hong-liang,HU Tong-xiu,SHANG Yu-min   

  1. Department of Obstetrics and Gynecology,Tianjin Hospital,Tianjin 300211,China
  • Received:2019-08-15 Revised:2019-12-04 Published:2020-02-15 Online:2020-02-07
  • Contact: LI Yang,E-mail:xiaolajiao1999@163.com E-mail:xiaolajiao1999@163.com
  • Supported by:
     

Abstract: Polycystic ovary syndrome (PCOS) is a common reproductive and metabolic disorder in women of childbearing age. It is often accompanied by metabolic abnormalities such as obesity, insulin resistance, androgen excess, and dyslipidemia. The metabolic disorder of PCOS is more complicated than simple reproductive disorders. Newly discovered myokine-Irisin is abnormally expressed in PCOS patients, which mainly induces "browning" of white adipose tissue, thereby increasing heat production and energy consumption. Previous studies shows that Irisin plays a protective role in obesity, type Ⅱ diabetes, lipid metabolism and cardiovascular diseases, non-alcoholic fatty liver and other metabolic disorders, but its role in the study of the occurrence and progression of PCOS disease is still unclear. Learning the role of Irisin in the pathogenesis of metabolic disorders in patients with PCOS provides new ideas for the diagnosis and treatment of PCOS.

Key words: Polycystic ovary syndrome, Insulin resistance, Metabolic diseases, Irisin

CLC Number: